Antiviral Agents in Pharmaceutical Chemistry
Unit Outcomes
- Trace the biosynthetic pathways involved in the action of antiviral agents.
- Classify and characterize the types of antiviral agents and enumerate drugs under each type.
- Identify and interpret structure-activity relationships of antiviral agents.
- Apply principles of medicinal chemistry in the synthesis and characterization of organic medicinal compounds.
Unit Outline
- Topics:
- Classification and characterization of antiviral agents.
- Structure-activity relationship of antiviral agents.
Checklist
- Read course outcomes and guide prior to class.
- Participate in discussions and online platforms (e.g., Canvas).
- Watch related instructional videos.
Overview of Viruses
- Definition: Smallest self-replicating organisms, categorized as parasitic.
- Structure:
- Nucleic Acid Core: Either DNA or RNA along with virus-specific enzymes.
- Capsid: Protein coat surrounding the nucleic acid core, sometimes with an outer lipid envelope.
- Complete viral particle is referred to as a virion.
Productive Infection
- Definition: Infection resulting in production of more viruses than initiated the infection.
- Burst Size: Number of infectious viruses produced per infected cell.
Classification of Viruses
- Baltimore Classification Scheme:
- DNA Viruses:
- Herpesvirus
- Papovavirus
- Adenovirus
- Hepadnavirus
- Poxvirus
- Parvovirus
- Most remaining are RNA viruses.
Infectious Process for Viruses (Steps):
- Adsorption
- Entry
- Uncoating
- Transcription
- Translation
- Assembly
- Release
Viral Cell Tropism
- Examples:
- HIV: CD4+ T lymphocytes, macrophages
- Influenza A: Respiratory epithelium
- Hepatitis viruses: Liver cells (hepatocytes)
- Common cold: Nasal epithelium.
Main Targets of Antiviral Agents
- Primary Targets: Viral enzymes including:
- Nucleic Acid Polymerases
- DNA-dependent DNA polymerase (DNA viruses).
- RNA-dependent RNA polymerase (RNA viruses).
- RNA-dependent DNA polymerase (for retroviruses).
- Proteases and Integrases involved in viral replication.
- Neuraminidases (orthomyxoviruses).
Mechanism of Action of Antivirals
- Entry Inhibitors: Target cell receptor sites to prevent viral entry.
- Uncoating Inhibitors: Block the uncoating process of the viral shell (e.g., amantadine).
- Synthesis Inhibitors:
- RNA synthesis inhibition (interferon, ribavirin).
- Genome replication inhibition via polymerase or reverse transcriptase inhibitors (nucleoside/nucleotide analogs).
- Assembly inhibition (protease inhibitors).
- Release inhibition through neuraminidase inhibitors.
Examples of Antiviral Agents
- Amantadine/Rimantadine:
- Inhibition of uncoating, effective only for influenza A virus.
- Neuraminidase Inhibitors:
- Zanamivir and Oseltamivir for influenza types A and B, effective before and after exposure.
- Oseltamivir is orally efficacious due to its ethyl ester modification.
- Interferon: Broad-spectrum antiviral agent; produced naturally in the body, effective against various RNA and DNA viruses.
- Nucleoside Antimetabolites:
- Idoxuridine: Used in herpes infection treatment.
- Acyclovir: An acyclic guanosine derivative effective against HSV and VZV, mechanism involves chain termination during DNA replication.
- Ganciclovir: More potent against CMV than acyclovir, with specific bioavailability concerns.
Reverse Transcriptase Inhibitors (RTIs)
- NRTIs:
- Examples include Zidovudine (AZT), Didanosine (ddI), Zalcitabine (ddC), Stavudine (d4T), and Lamivudine (3TC).
- NNRTIs: Non-nucleoside analogues that bind reversely and inhibit viral reverse transcriptase.
- Integrase Inhibitors:
- Prevents viral DNA from integrating into the host genome (e.g., Dolutegravir).
- Protease Inhibitors:
- Landscape of drugs targeting the protease enzyme critical for viral maturation (e.g., Ritonavir).
Adverse Effects of Antiviral Agents
- Common adverse effects for several antivirals include nausea, diarrhea, myelosuppression, peripheral neuropathy, and possible renal impairment due to different agents.
Recent Developments in Antiviral Therapy
- Notable mentions include Remdesivir for COVID-19,
and various combinations aimed at providing effective treatment regimens for chronic infections, particularly for HIV and Hepatitis.